Novartis CEO warns that data on Covid-19 drugs is missing
Business was good for Novartis in the first quarter of the year.
Keystone / Georgios Kefalas
Potential pharmaceutical solutions to combat Covid-19 must have strong clinical data to back their efficacy, according to Novartis boss Vasant Narasimhan.
This content was published on
2 minutes
SDA-Keystone/ac
Español
es
Novartis: faltan datos sobre fármacos anticoronavirus
Clinical studies that are properly conducted are necessary to really determine the benefit of drugs, Narasimhan told the Reuters news agency on Tuesday. Only a few drugs had met the standards so far, he said.
The Swiss pharmaceutical company has initiated a clinical study with the anti-malarial drug hydroxychloroquine. Last month he told the Swiss media that pre-clinical studies in animals as well as the first data from clinical studies showed that hydroxychloroquine kills the coronavirus. While the therapy is not yet available, Narasimhan hinted that the first study results could be available in summer.
The Basel-based company also announced its first quarter results on Tuesday, reporting a 11% increase in net sales and a turnover of $12.28 billion (CHF12 billion). Novartis says it has managed to weather the coronavirus storm to keep production facilities going.
“Our operations and product demand remain very stable and strong. Mitigating actions helped to ensure minimal disruption to supply chain and ability to meet forward purchasing demand,” according to a company statement.
Forward purchasing and lower spending meant that Novartis made an extra $400 million due to the coronavirus pandemic in the first quarter. However, it is likely that these gains will be reversed over the remainder of 2020, the company cautioned.
More
More
Swiss hospitals launch drug trial to prevent Covid-19 infection
This content was published on
Researchers in Geneva and Basel have launched a clinical trial to test two drugs on people that have been in contact with Covid-19 patients.
Swiss committee wants to end government resignations during legislative term
This content was published on
Members of the Federal Council should no longer be able to leave office before the end of their term, according to a House of Representatives committee.
Swiss government seat: Ritter and Pfister nominated to succeed Amherd
This content was published on
Markus Ritter from St Gallen and Martin Pfister from Zug were officially nominated by the Centre Party on Friday to succeed Defence Minister Viola Amherd.
Top Swiss court rejects Russian request for administrative tax assistance
This content was published on
There is currently no reason to transmit banking information to the Russian Federation, the Swiss Federal Court has ruled.
After strike by radiologists, doctors demonstrate in Bern
This content was published on
Following a strike by radiology technicians in Fribourg, doctors, vets, dentists and chiropractors expressed their frustration on Friday outside parliament in the Swiss capital.
Eurovision and bleak world situation are top themes at Basel carnival
This content was published on
The Eurovision Song Contest and the gloomy global situation are among the main themes of Basel Fasnacht (carnival) this year.
Prices of Swiss investment properties continue to rise despite stagnating rents
This content was published on
Although rents in Switzerland stagnated or fell in the final quarter of last year, prices for investment properties continued to rise. Both apartment buildings and office properties have become more expensive.
Probe into wrong Swiss pension figures clears federal office
This content was published on
Employees of the Swiss Federal Social Insurance Office (FSIO) did not breach their duty of care when calculating pension prospects, an investigation has concluded.
This content was published on
Hotels in the southern Swiss canton of Ticino welcomed significantly more guests last December than in the same month of the previous year.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
‘Anti-malaria drug can kill coronavirus’: Novartis chief
This content was published on
Swiss pharmaceutical giant Novartis believes the anti-malaria drug hydroxychloroquine offers one of the best hopes to combat coronavirus.
WHO and Roche launch trials of potential coronavirus treatments
This content was published on
Roche is launching a clinical trial of a potential new Covid-19 drug, adding to rapidly growing investments in combating coronavirus.
Balancing hope and science in the search for a coronavirus cure
This content was published on
The debate surrounding the antimalarial drug hydroxychloroquine epitomises companies' balancing act between hope and scientific realities.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.